1 interaction related to rapamycin
Sirolimus is a CYP3A4 and P-glycoprotein substrate with a narrow therapeutic window and high baseline interpatient variability. The FDA-approved Rapamune label states that grapefruit juice inhibits the CYP3A4-mediated metabolism of sirolimus and must not be taken with or used to dilute the drug, because unpredictable, large rises in blood levels can cause nephrotoxicity, infection, and graft injury.